|
294 Companies |
|
490 Products |
|
490 Products |
|
198 Mechanisms of Action |
|
25 Trials |
|
7787 News |
|
| «12...145146147148149150151152153154155...156157» |
- ||||||| dronabinol (BX-1) / Bionorica
Trial completion: Efficacy and Safety of the Pain Relieving Effect of Dronabinol in Central Neuropathic Pain Related to Multiple Sclerosis (clinicaltrials.gov) - Feb 1, 2012
P3, N=240, Completed, Sponsor: Bionorica Research GmbH
Active, not recruiting --> Completed
- ||||||| Orencia (abatacept) / BMS
Trial completion, P3 data, IO biomarker: A Phase III Study of Abatacept in Patients With Rheumatoid Arthritis and an Inadequate Response to Methotrexate (clinicaltrials.gov) - Feb 1, 2012
P3, N=113, Completed, Sponsor: Bristol-Myers Squibb
Active, not recruiting --> Completed Active, not recruiting --> Completed
- | Tysabri (natalizumab) / Biogen, Royalty
Trial termination: SURPASS: Study Evaluating Rebif, Copaxone, and Tysabri for Active Multiple Sclerosis (clinicaltrials.gov) - Feb 1, 2012
P3, N=84, Terminated, Sponsor: Biogen Idec
Active, not recruiting --> Completed Active, not recruiting --> Terminated; Due to significantly slower than expected enrollment, the Sponsor decided to terminate the study.
- |||| Rituxan (rituximab) / Roche
Combination therapy: Safety and Tolerability of Rituxan With Methotrexate and Etanercept or Methotrexate and Adalimumab in Patients With Active Rheumatoid Arthritis (clinicaltrials.gov) - Feb 1, 2012
P2, N=54, Completed, Sponsor: Biogen Idec
Active, not recruiting --> Terminated; Due to significantly slower than expected enrollment, the Sponsor decided to terminate the study. Active, not recruiting --> Completed
- Trial completion: STRASS: Spacing of TNF-blocker Injections in Rheumatoid Arthritis Study (clinicaltrials.gov) - Jan 31, 2012
P4, N=250, Completed, Sponsor: Assistance Publique - Hôpitaux de Paris
Active, not recruiting --> Completed Recruiting --> Completed
- Clinical: The Effect of Guided Imagery in Children With Type 1 Diabetes Mellitus on Glucose Levels and on Glycemic Control (clinicaltrials.gov) - Jan 31, 2012
P=N/A, N=14, Not yet recruiting, Sponsor: Assaf-Harofeh Medical Center
- | BIAsp 30 (biphasic insulin aspart 30/70 biosimilar) / Novo Nordisk
New P1 trial: Comparison of Single Dose and Steady State Pharmacodynamics of Biphasic Insulin Aspart 30 and 70 in Subjects With Type 1 Diabetes (clinicaltrials.gov) - Jan 31, 2012
P1, N=27, Completed, Sponsor: Novo Nordisk
- || Betaseron (IFN-?-1b) / Bayer
Enrollment closed, Adherence: SEPLUS: Prospective, Multicenter Non Interventional Study to Evaluate Adherence to Betaferon Over a 2 Years Period (clinicaltrials.gov) - Jan 31, 2012
P=N/A, N=74, Active, not recruiting, Sponsor: Bayer
Recruiting --> Completed Recruiting --> Active, not recruiting
- givinostat (ITF2357) / Italfarmaco
Trial termination: Efficacy and Safety Dose Finding Study of Givinostat to Treat Polyarticular Course Juvenile Idiopathic Arthritis (clinicaltrials.gov) - Jan 30, 2012
P2, N=16, Terminated, Sponsor: Italfarmaco
Recruiting --> Active, not recruiting Recruiting --> Terminated; The primary reason for the decision to discontinue the study is lack of enrolment; this decision is not related to any tolerability concerns with Givinostat
- givinostat (ITF2357) / Italfarmaco
Enrollment change: Efficacy and Safety Dose Finding Study of Givinostat to Treat Polyarticular Course Juvenile Idiopathic Arthritis (clinicaltrials.gov) - Jan 30, 2012
P2, N=16, Terminated, Sponsor: Italfarmaco
Recruiting --> Terminated; The primary reason for the decision to discontinue the study is lack of enrolment; this decision is not related to any tolerability concerns with Givinostat N=20 --> 16
- |||| tabalumab (LY2127399) / Eli Lilly
Trial completion: An Open Label Extension Study in Participants With Rheumatoid Arthritis (clinicaltrials.gov) - Jan 30, 2012
P2, N=183, Completed, Sponsor: Eli Lilly and Company
N=20 --> 16 Active, not recruiting --> Completed
- New P2 trial, Adherence: Cognitive Behavioral Therapy (CBT) for Adherence and Depression in Type 1 Diabetes (clinicaltrials.gov) - Jan 30, 2012
P2, N=9, Completed, Sponsor: Massachusetts General Hospital
- | BIAsp 30 (biphasic insulin aspart 30/70 biosimilar) / Novo Nordisk
New P1 trial: Pharmacokinetics of Biphasic Insulin Aspart 30 and 70 in Subjects With Type 1 Diabetes (clinicaltrials.gov) - Jan 30, 2012
P1, N=26, Completed, Sponsor: Novo Nordisk
- ||||| New P4 trial: Study Looking at Longitudinal Changes in Fatigue and Health Status in Rheumatoid Arthritis (RA) Patients Treated With Subcutaneous Anti-TNF-α Therapy (clinicaltrials.gov) - Jan 29, 2012
P4, N=75, Active, not recruiting, Sponsor: Pfizer
- |||||||||| Cimzia (certolizumab pegol) / Astellas, UCB
New P3 trial, Combination therapy: A Multi-center, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Certolizumab Pegol in Combination With Methotrexate in the Treatment of Disease Modifying Antirheumatic Drugs (DMARD)-naïve Adults With Early Active Rheumatoid Arthritis (clinicaltrials.gov) - Jan 29, 2012
P3, N=880, Active, not recruiting, Sponsor: UCB, Inc.
- ||||||| Lemtrada (alemtuzumab) / Sanofi
Trial completion: CARE-MS II: Comparison of Alemtuzumab and Rebif (clinicaltrials.gov) - Jan 29, 2012
P3, N=840, Completed, Sponsor: Genzyme, a Sanofi Company
Active, not recruiting --> Completed Active, not recruiting --> Completed
- ||| sifalimumab (MDX-1103) / AstraZeneca
Enrollment closed: A Study to Evaluate the Long-Term Safety of MEDI-545 in Adult Subjects With Systemic Lupus Erythematosus or Myositis (clinicaltrials.gov) - Jan 26, 2012
P1/2, N=260, Active, not recruiting, Sponsor: MedImmune LLC
Active, not recruiting --> Completed Recruiting --> Active, not recruiting
- |||||||||| Promacta (eltrombopag) / Novartis
New P3 trial: PETIT2: Study of a New Medication for Childhood Chronic Immune Thrombocytopenia (ITP), a Blood Disorder of Low Platelet Counts That Can Lead to Bruising Easily, Bleeding Gums, and/or Bleeding Inside the Body. (clinicaltrials.gov) - Jan 26, 2012
P3, N=92, Completed, Sponsor: GlaxoSmithKline
- baminercept (BG 9924) / Biogen
Enrollment change: Dose Escalation Study to Evaluate the Penetration and Pharmacodynamic Effects of Baminercept in the Cerebrospinal Fluid (CSF)and Safety in Subjects With Secondary Progressive Multiple Sclerosis (SPMS) (clinicaltrials.gov) - Jan 25, 2012
P1/2, N=0, Withdrawn, Sponsor: Biogen Idec
Recruiting --> Active, not recruiting N=80 --> 0
- |||||||||| Cimzia (certolizumab pegol) / Astellas, UCB
New P3 trial, Combination therapy: A Multi-center, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Certolizumab Pegol in Combination With Methotrexate in the Treatment of Disease Modifying Antirheumatic Drugs (DMARD)-naïve Adults With Early Active Rheumatoid Arthritis (clinicaltrials.gov) - Jan 25, 2012
P3, N=880, Active, not recruiting, Sponsor: UCB Pharma SA
- ||| Avonex (recombinant IFN-β-1a) / Biogen
Trial completion, Compliance: COMPASS: COMPliance With Avonex® PS in Patients With Relapsing-Remitting MS (clinicaltrials.gov) - Jan 25, 2012
P=N/A, N=1000, Completed, Sponsor: Biogen Idec
N=80 --> 0 Active, not recruiting --> Completed
- AGS-009 / CoImmune
Enrollment change: An Investigation of AGS-009 in Patients With Systemic Lupus Erythematosus (SLE) (clinicaltrials.gov) - Jan 25, 2012
P1, N=13, Completed, Sponsor: Argos Therapeutics
Active, not recruiting --> Completed N=24 --> 13
- ||||| Promacta (eltrombopag) / Novartis
Enrollment change: EXTEND (Eltrombopag Extended Dosing Study) (clinicaltrials.gov) - Jan 25, 2012
P3, N=302, Active, not recruiting, Sponsor: GlaxoSmithKline
N=24 --> 13 N=400 --> 302
- | AGS-009 / CoImmune
Trial completion: An Investigation of AGS-009 in Patients With Systemic Lupus Erythematosus (SLE) (clinicaltrials.gov) - Jan 25, 2012
P1, N=13, Completed, Sponsor: Argos Therapeutics
N=400 --> 302 Recruiting --> Completed
- Trial withdrawal: A Clinical Investigation of the Comprehensive®, BioModular®, and Bi-Angular® Shoulder Systems (clinicaltrials.gov) - Jan 24, 2012
P=N/A, N=0, Withdrawn, Sponsor: Biomet Orthopedics, LLC
Recruiting --> Completed Terminated --> Withdrawn
- Enrollment change: A Clinical Investigation of the Comprehensive®, BioModular®, and Bi-Angular® Shoulder Systems (clinicaltrials.gov) - Jan 24, 2012
P=N/A, N=0, Withdrawn, Sponsor: Biomet Orthopedics, LLC
Terminated --> Withdrawn N=200 --> 0
- | Enrollment closed, Pneumococcal vaccines: VACCILUP: Safety Study of Two Vaccine Strategies in Patients With Systemic Lupus Erythematosus (clinicaltrials.gov) - Jan 24, 2012
P2/3, N=106, Active, not recruiting, Sponsor: Assistance Publique - Hôpitaux de Paris
N=200 --> 0 Recruiting --> Active, not recruiting
- Trial initiation date: Effect of a Medium Chain Triglyceride Supplemented Diet on Cognitive Function and Brain Activation in Type 1 Diabetes. (clinicaltrials.gov) - Jan 24, 2012
P=N/A, N=30, Recruiting, Sponsor: Yale University
Recruiting --> Active, not recruiting Initiation date: Mar 2011 --> Jan 2012
- |||||||||| New P3 trial: Comparison of Biphasic Human Insulin 30 With Biphasic Insulin Aspart in Subjects With Diabetes (clinicaltrials.gov) - Jan 24, 2012
P3, N=666, Completed, Sponsor: Novo Nordisk
- New P2 trial: Comparison of Closed-loop Operation After Morning Meal With and Without Carbohydrate Counting (clinicaltrials.gov) - Jan 24, 2012
P2, N=12, Completed, Sponsor: Institut de Recherches Cliniques de Montreal
- ||| Trial completion: A Survey to Evaluate Diabetes Management, Control, Chronic Complications, Psychosocial Aspects of Children With Type 1 Diabetes (clinicaltrials.gov) - Jan 24, 2012
P=N/A, N=365, Completed, Sponsor: Novo Nordisk
Initiation date: Mar 2011 --> Jan 2012 Enrolling by invitation --> Completed
- New P2 trial: Oral Testosterone for Fatigue in Male Multiple Sclerosis Patients (clinicaltrials.gov) - Jan 23, 2012
P2, N=50, Recruiting, Sponsor: Health Sciences Centre, Winnipeg, Manitoba
- | otilimab (GSK3196165) / GSK
New P1/2 trial: Phase Ib Study to Evaluate MOR103 in Multiple Sclerosis (clinicaltrials.gov) - Jan 23, 2012
P1/2, N=30, Completed, Sponsor: MorphoSys AG
- Enrollment open: Defining the Anti-inflammatory Role of Lipoic Acid in Multiple Sclerosis (clinicaltrials.gov) - Jan 23, 2012
P1, N=60, Recruiting, Sponsor: Portland VA Medical Center
Enrolling by invitation --> Completed Not yet recruiting --> Recruiting
- Trimesta (estriol oral) / Synthetic Biologics
Enrollment closed: A Combination Trial of Copaxone Plus Estriol in Relapsing Remitting Multiple Sclerosis (RRMS) (clinicaltrials.gov) - Jan 22, 2012
P2, N=150, Active, not recruiting, Sponsor: University of California, Los Angeles
Not yet recruiting --> Recruiting Recruiting --> Active, not recruiting
- Trial completion: American Ginseng Treatment for Multiple Sclerosis Related Fatigue (clinicaltrials.gov) - Jan 22, 2012
P2, N=56, Completed, Sponsor: Oregon Health and Science University
Recruiting --> Active, not recruiting Active, not recruiting --> Completed
- ||||| Rebif (human IFN-β-1a) / EMD Serono
New P2 trial: EMR200136-549: Dietary Supplement of Curcumin in Subjects With Active Relapsing Multiple Sclerosis Treated With Subcutaneous Interferon Beta 1a (clinicaltrials.gov) - Jan 19, 2012
P2, N=80, Recruiting, Sponsor: Merck KGaA
- || Enrollment closed: Vanguard Complete Knee Versus Vanguard High Flex Rotating Platform (RP) Knee Study (clinicaltrials.gov) - Jan 19, 2012
P=N/A, N=300, Active, not recruiting, Sponsor: Biomet, Inc.
Active, not recruiting --> Completed Recruiting --> Active, not recruiting
- ||||| Lemtrada (alemtuzumab) / Sanofi
Enrollment closed: An Extension Protocol for Multiple Sclerosis Patients Who Participated in Genzyme-Sponsored Studies of Alemtuzumab (clinicaltrials.gov) - Jan 19, 2012
P3, N=1322, Active, not recruiting, Sponsor: Genzyme, a Sanofi Company
Recruiting --> Active, not recruiting Enrolling by invitation --> Active, not recruiting
- Zinbryta (daclizumab) / Biogen, AbbVie, Rituxan (rituximab) / Biogen, Zenyaku Holdings, Roche
Trial termination: B-Lymphocyte Immunotherapy in Islet Transplantation (clinicaltrials.gov) - Jan 19, 2012
P2, N=2, Terminated, Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
Enrolling by invitation --> Active, not recruiting Completed --> Terminated; Lack of efficacy
- Zinbryta (daclizumab) / Biogen, AbbVie, Rituxan (rituximab) / Biogen, Zenyaku Holdings, Roche
Enrollment change: B-Lymphocyte Immunotherapy in Islet Transplantation (clinicaltrials.gov) - Jan 19, 2012
P2, N=2, Terminated, Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
Completed --> Terminated; Lack of efficacy N=12 --> 2
- ||||||| Trial completion, HEOR: Tolerability and Safety and Health Outcomes in Relapsing Multiple Sclerosis (MS) Patients (clinicaltrials.gov) - Jan 18, 2012
P3, N=2417, Completed, Sponsor: Novartis
N=12 --> 2 Recruiting --> Completed
- | Xeljanz (tofacitinib) / Pfizer
Clinical: Pharmacokinetics Of CP-690,550 In Pediatric Patients With Juvenile Idiopathic Arthritis (JIA) (clinicaltrials.gov) - Jan 18, 2012
P1, N=24, Recruiting, Sponsor: Pfizer
- || Privigen (human immune globulin intravenous 10%) / CSL Behring
Trial completion: Study of Efficacy and Safety of Privigen in Subjects With Chronic Inflammatory Demyelinating Polyneuropathy (clinicaltrials.gov) - Jan 18, 2012
P3, N=31, Completed, Sponsor: CSL Behring
Recruiting --> Completed Active, not recruiting --> Completed
- | New P2 trial: Effectiveness of 3,4-Diaminopyridine in Lambert-Eaton Myasthenic Syndrome (clinicaltrials.gov) - Jan 17, 2012
P2, N=30, Recruiting, Sponsor: Jacobus Pharmaceutical
- |||| Privigen (human immune globulin intravenous 10%) / CSL Behring
Enrollment open, Preclinical: A Safety Study of Intravenous Immunoglobulin in Patients With Chronic Immune Thrombocytopenic Purpura (ITP) (clinicaltrials.gov) - Jan 17, 2012
P4, N=150, Recruiting, Sponsor: CSL Behring
Active, not recruiting --> Completed Not yet recruiting --> Recruiting
- || Enrollment closed: Living Well With Rheumatoid Arthritis (clinicaltrials.gov) - Jan 17, 2012
P=N/A, N=100, Active, not recruiting, Sponsor: Brigham and Women's Hospital
Not yet recruiting --> Recruiting Completed --> Active, not recruiting
- | New P2 trial: IFOPI: Evaluation of Functional Insulin Therapy in Type 1 Diabetic Patients (clinicaltrials.gov) - Jan 17, 2012
P2, N=60, Recruiting, Sponsor: University Hospital, Montpellier
- Trial completion: Matrix Metalloproteinases and Diabetic Nephropathy (clinicaltrials.gov) - Jan 17, 2012
P=N/A, N=330, Completed, Sponsor: Arkansas Children's Hospital Research Institute
Completed --> Active, not recruiting Active, not recruiting --> Completed
- ||||| tacrolimus intravenous / Generic mfg.
New P4 trial: TREASURE: A Study is to Assess Efficacy and Safety of Tacrolimus in Active Rheumatoid Arthritis Patients Who Showed Unsuccessful Response to Existing Disease Modifying Antirheumatic Drugs (DMARDs) (clinicaltrials.gov) - Jan 16, 2012
P4, N=96, Recruiting, Sponsor: Astellas Pharma Inc